Semaglutide 3mg — is this a weight-loss dose?

Why does a semaglutide 3mg tablet exist?

Rybelsus was the first oral semaglutide approved anywhere in the world. Novo Nordisk developed it for adults with type 2 diabetes who wanted an alternative to injections, and the MHRA licensed it in the UK for that purpose. The 3mg tablet is the introductory dose, taken for the first month purely to let the body adjust to the medicine before stepping up to 7mg and then 14mg. It has no therapeutic blood-sugar effect at 3mg; the whole point of that first month is tolerability, not treatment.

So if you've spotted a 3mg semaglutide tablet in a search result or on a shelf, it is a diabetes medicine in its starting phase. It is not a low-level weight-loss option, and it is not a cheaper entry point into Wegovy. The semaglutide overview explains how the molecule works across both indications, but the clinical paths diverge sharply once you move past the mechanism.

Worth knowing: because Rybelsus and Wegovy share the same active ingredient, some people assume the doses translate across products. They don't. Bioavailability, co-formulation, and the approved dose ranges are different, and if you want to understand how the formulations compare, the semaglutide 1 page is a useful place to start before looking at the semaglutide 2 page, which covers a similar confusion that arises with injection strengths.

What dose schedule does the Wegovy weight-loss tablet actually follow?

On 11 June 2026 the MHRA approved Wegovy tablets as the first oral GLP-1 medicine licensed in the UK specifically for weight management. The UK was the first country in Europe to grant that approval. The dose ladder runs 1.5mg, then 4mg, then 9mg, and finally 25mg, with at least a month at each step before moving up. A prescriber decides the pace based on how well you're tolerating each level.

The 25mg maintenance dose is where the trial evidence sits. In the OASIS 4 phase 3 trial (307 adults with obesity or overweight plus at least one weight-related condition, 64 weeks), average weight loss was around 13.6% compared with roughly 2.4% on placebo. Among participants who stayed fully adherent throughout, that figure rose to about 17%. Those are the Wegovy numbers, not Rybelsus numbers, and not numbers associated with a 3mg dose of anything.

One practical difference from the injection: Wegovy tablets don't need refrigerating, which makes them considerably easier to manage day-to-day. Take yours first thing in the morning before anything else (before the kettle goes on, before coffee, before any other medicines) with no more than a small sip of plain water, then wait at least 30 minutes before eating or drinking anything else.

Could Rybelsus be prescribed off-label for weight loss?

This question comes up because the underlying molecule, semaglutide, does affect appetite and body weight. Clinically, the MHRA licenses medicines for specific indications, and the NHS and MHRA are both clear: semaglutide in its Rybelsus form is licensed for type 2 diabetes. Prescribing it for weight loss would be off-label, and responsible prescribers follow licensed pathways. The availability of a properly licensed oral weight-loss option (Wegovy tablets) removes any clinical rationale for reaching for Rybelsus instead.

The MHRA has also been explicit that GLP-1 medicines are not assessed for quick or cosmetic weight loss, and that people should only access them through legitimate clinical routes. Any seller offering a 3mg semaglutide tablet for weight loss, without a proper clinical assessment, is operating outside that framework. You can report concerns through the MHRA Yellow Card scheme.

For anyone exploring weight management options in more detail, the weight-loss treatment overview sets out what's currently licensed in the UK and what the clinical criteria look like. Pricing context for those treatments is covered separately, you can find a breakdown of where to access Wegovy and what legitimate private supply involves.

What's the right starting point if you're looking at semaglutide for weight management?

If your search for semaglutide 3mg was actually a search for a weight-loss option, the licensed routes are Wegovy (injection or tablet) and Mounjaro (tirzepatide). Both are prescription-only medicines, a prescriber assesses your BMI, health history and any existing conditions before anything is issued. There is no over-the-counter path and no shortcut through a diabetes product.

The Wegovy injection follows its own titration from 0.25mg upward, while the tablet starts at 1.5mg. The semaglutide injection at lower doses page covers questions about that part of the schedule. For anyone already on a semaglutide injection and thinking about switching to the tablet, that's a clinical conversation, dose equivalence isn't straightforward, and the Wegovy SmPC is the definitive reference for that decision.

Our prescribers at nume see these questions regularly. If you'd like a clinical assessment to find out which treatment, if any, is appropriate for you, a free consultation is the place to start, reviewed the same day by a GPhC-registered prescriber, not a screening algorithm. Our clinical team can walk you through what's licensed, what the eligibility criteria look like for your circumstances, and what to expect from treatment.